Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma.
- Author:
Shinae YU
1
;
Sung Woo RYU
;
Kyoung Ha KIM
;
Se Hyoung KIM
;
Nam Su LEE
;
Sung Kyu PARK
;
Jong Ho WON
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. kyoungha@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Bortezomib;
Multiple myeloma;
Tumor lysis syndrome
- MeSH:
Boronic Acids;
Humans;
Lymphoproliferative Disorders;
Multiple Myeloma;
Organothiophosphorus Compounds;
Pyrazines;
Tumor Burden;
Tumor Lysis Syndrome;
Bortezomib
- From:Soonchunhyang Medical Science
2013;19(1):31-33
- CountryRepublic of Korea
- Language:English
-
Abstract:
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed.
